STOCK TITAN
  1. Home
  2. News
  3. ORGS

Orgenesis Inc - ORGS STOCK NEWS

Welcome to our dedicated news page for Orgenesis (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orgenesis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orgenesis's position in the market.

News
Orgenesis Provides Year End Business Update
Rhea-AI Summary
Orgenesis Inc. provided a year-end business update, highlighting major transformations, such as acquiring full ownership of Octomera, securing a $2.3 million investment at a premium price, and entering into a strategic collaboration agreement. The company focuses on decentralized production for cell and gene therapies, aiming to reduce costs and expand production capacity. Despite industry challenges, Orgenesis remains optimistic about the future, leveraging grants and partnerships to advance its therapeutic pipeline and meet growing demand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
Rhea-AI Summary
Germfree and Orgenesis Inc. announce a strategic partnership to advance cell and gene therapy production. The collaboration aims to reduce production costs, increase accessibility to treatments, and revolutionize the bio-manufacturing industry. Orgenesis will co-market its Octomera platform with Germfree, enhancing market expansion opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
partnership
-
News
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
Rhea-AI Summary
Orgenesis Inc. (ORGS) CEO, Vered Caplan, to present at Bioprocessing Summit Europe on overcoming conventional CGT processing challenges with POCare solutions. The conference aims to advance manufacturing and quality control of biological and genetic therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11%
Tags
conferences
News
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
Rhea-AI Summary
Orgenesis Inc. has been awarded a €1.5 million grant from the Walloon government in Belgium for its EXOFASTTRACK project, focusing on manufacturing therapeutic exosomes. The project aims to accelerate the development of multiple therapeutic exosomes for clinical evaluation, potentially reducing production costs and promoting accessibility to life-saving therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
-
News
Orgenesis Inc. Announces $2.3 Million Private Placement
Rhea-AI Summary
Orgenesis Inc. announced a private placement agreement with accredited investors for the sale of shares and warrants, expecting to raise around $2.3 million. The deal includes 2,272,719 shares of common stock and corresponding warrants at different exercise prices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.65%
Tags
none
-
News
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
Rhea-AI Summary
Orgenesis Inc. (ORGS) announces a €2.0 million grant from the Walloon Government in Belgium for AI monitoring of decentralized ATMP manufacturing. The project aims to enhance the production of advanced therapy medicinal products through AI-based approaches. The grant is part of a larger initiative with an €81 million budget over three years to drive technological innovation in the ATMP sector, creating jobs and fostering partnerships. Orgenesis plans to utilize the grant to accelerate the placement of a CAR-T dedicated facility in Belgium, making CAR-T therapies more affordable in the region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
AI
News
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
Rhea-AI Summary
Orgenesis Inc. (ORGS) announced the acquisition of Metalmark's 25% stake in Octomera LLC, giving Orgenesis 100% ownership of the cell processing services subsidiary. Metalmark will receive a 5% royalty of Octomera's net revenue for 2025-2027 and a portion of proceeds in case of a change of control in the next 10 years. CEO Vered Caplan highlighted the industry's need for decentralized cell therapy and the support from FDA and EMEA regulators. The company's focus on developing proprietary therapeutics and advancing oncology therapeutics was emphasized. Newly appointed CFO Victor Miller expressed confidence in the company's expertise and portfolio, thanking Metalmark for their support. Public updates on the company's therapeutics and technologies are expected throughout 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
acquisition
-
News
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
Rhea-AI Summary
Orgenesis Inc. (NASDAQ: ORGS) ranked 171 on the Deloitte Technology Fast 500™, recognizing the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. CEO Vered Caplan highlighted the company's decentralized approach to manufacturing advanced cell and gene therapies, aiming to lower costs, streamline logistics, and expand capacity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
News
Orgenesis Provides Business Update for the Third Quarter of 2023
Rhea-AI Summary
Orgenesis Inc. (NASDAQ: ORGS) provided a business update for the third quarter ended September 30, 2023, highlighting the advances in the rollout of its POCare Platform and POCare Therapies. The CEO, Vered Caplan, emphasized the expansion of partnerships with California Davis and CGT Global for streamlined production and accelerated research and clinical trials. The Company's focus on advancing cell and gene therapies across the U.S., Europe, the Middle East, and other regions is evident in its efforts to build a decentralized network and infrastructure through Octomera, aiming to meet the growing demand for these advanced therapeutic services. Additionally, Orgenesis is advancing its therapeutic pipeline, spanning multiple clinical programs in immuno-oncology, anti-viral, metabolic/autoimmune diseases, and tissue regeneration, while leveraging government grants and funding from regional partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
News
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
Rhea-AI Summary
Orgenesis Inc. (ORGS) announces a registered direct offering to sell $1.1 million of common stock and warrants to a single institutional investor, with a combined effective purchase price of $0.78 per share. Titan Partners Group is the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.26%
Tags
offering
Stock ORGS logo
Orgenesis Inc

Nasdaq:ORGS

ORGS Rankings

#5198 Ranked by Market Cap
#3932 Ranked by Stock Gains
N/A Ranked by Dividends

ORGS Stock Data

16.84M
28.14M
20.99%
6.78%
0.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Germantown

About ORGS

orgenesis inc (orgs) is a medical device company located in 21 sparrow cir, white plains, new york, united states.